Key Insights

Highlights

Success Rate

92% trial completion (above average)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

4.0%

1 terminated out of 25 trials

Success Rate

91.7%

+5.1% vs benchmark

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

18%

2 of 11 completed with results

Key Signals

2 with results92% success

Data Visualizations

Phase Distribution

15Total
Not Applicable (6)
Early Phase 1 (1)
Phase 1 (1)
Phase 1/2 (2)
Phase 2 (5)

Trial Status

Completed11
Unknown5
Recruiting4
Active Not Recruiting2
Enrolling By Invitation1
Not Yet Recruiting1

Trial Success Rate

91.7%

Benchmark: 86.6%

Based on 11 completed trials

Clinical Trials (25)

Showing 20 of 20 trials
NCT07804719Active Not RecruitingPrimary

Possible Sarcopenia, Sarcopenia, and Functional Status in Patients With Primary Sjögren's Syndrome

NCT06440525Phase 2Active Not RecruitingPrimary

A Study of RSLV-132 in Females With Sjögren's Disease

NCT07324733Not ApplicableRecruitingPrimary

Exploring the Novel Value of PSMA PET in Sjögren's Syndrome: Integrated Analysis With Established FAPI PET Imaging

NCT03126383CompletedPrimary

Inflammatory Myopathies in Primary Sjögren's Syndrome

NCT07246096Early Phase 1Recruiting

Exploratory Clinical Study on the Safety and Efficacy of Anti- CD19/BCMA U CAR-T Cell Injection for the Treatment of Relapsed/Refractory Autoimmune Diseases

NCT03509064RecruitingPrimary

Medico-economic and Quality of Life Impact of Sjogren-associated Small Fiber Neuropathy

NCT07375524Phase 2Not Yet RecruitingPrimary

A Phase 2 Study on the Safety and Efficacy of the Anti-BAFF-R Monoclonal Antibody, ESG206, in Patients With Primary Sjogren Syndrome

NCT03614299CompletedPrimary

Eye Dryness Evaluation in Primary Sjögren's Syndrome

NCT06528197RecruitingPrimary

Construction of Clinical Model of Primary Sjogren's Syndrome Combined Traditional Chinese and Western Medicine

NCT06519617Phase 2Enrolling By InvitationPrimary

Study on Optimization and Evaluation of Integrated Chinese and Western Medicine for pSS Glandular Damage

NCT04093531Phase 1CompletedPrimary

Pilot Trial of Ustekinumab for Primary Sjögren's Syndrome

NCT06361745Not ApplicableUnknown

Early Clinical Study of UTAA09 Injection in the Treatment of Relapsed/Refractory Autoimmune Diseases

NCT04960605Not ApplicableCompleted

Prognosis of Dental Implants in Patients With Primary Sjögren's Syndrome

NCT06049368Phase 1/2UnknownPrimary

68Ga-P16-093 PET/CT Imaging in the Salivary Gland

NCT04700280Phase 2TerminatedPrimary

A Study Evaluating the Effects of GLPG3970 Given as an Oral Treatment for 12 Weeks in Adults With Active Primary Sjögren's Syndrome (pSS)

NCT05670535CompletedPrimary

Sjögren and Gynecologic Considerations

NCT05380804Completed

Cutaneous Silent Period Assessment in Primary Sjögren's Syndrome

NCT04830644Phase 2UnknownPrimary

A Study to Evaluate the Efficacy and Safety of Iguratimod Compared to Placebo in Patients With Active Primary Sjogren's Syndrome.

NCT04816370Not ApplicableCompletedPrimary

Effects of Primary Sjögren's Syndrome on Female Genitalia and Sexual Functions

NCT03226444Phase 1/2CompletedPrimary

Lacripep™ in Subjects With Dry Eye Associated With Primary Sjögren's Syndrome

Scroll to load more

Research Network

Activity Timeline